Anemia due to chemotherapy; anemia in neoplastic disease (D63.0); aplastic anemia due to antineoplastic chemotherapy (D61.1); Antineoplastic chemotherapy induced anemia ICD-10-CM Diagnosis Code D64.81
ICD-10-CM Diagnosis Code D64.81 [convert to ICD-9-CM] Anemia due to antineoplastic chemotherapy. Anemia due to chemotherapy; anemia in neoplastic disease (D63.0); aplastic anemia due to antineoplastic chemotherapy (D61.1); Antineoplastic chemotherapy induced anemia. ICD-10-CM Diagnosis Code D64.81.
Oct 01, 2021 · 2016 (effective 10/1/2015): New code (first year of non-draft ICD-10-CM) 2017 (effective 10/1/2016): No change 2018 (effective 10/1/2017): No change 2019 (effective 10/1/2018): No change 2020 (effective 10/1/2019): No change 2021 (effective 10/1/2020): No change 2022 (effective 10/1/2021): No ...
Oct 01, 2021 · Anemia in neoplastic disease D63.0 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2022 edition of ICD-10-CM D63.0 became effective on October 1, 2021. This is the American ICD-10-CM version of D63.0 - other international versions of ...
Complications of Cancer TreatmentICD-10-CM CodeICD-10-CM DescriptionD61.810Antineoplastic chemotherapy induced pancytopeniaD64.81Anemia due to antineoplastic chemotherapyD70.1Agranulocytosis secondary to cancer chemotherapyJ34.81Nasal mucositis (ulcerative) (due to antineoplastic and immunosuppressive drugs)19 more rows
81.
ICD-10 | Antineoplastic chemotherapy induced pancytopenia (D61. 810)
T45. 1X5A - Adverse effect of antineoplastic and immunosuppressive drugs [initial encounter] | ICD-10-CM.
Agranulocytosis secondary to cancer chemotherapy D70. 1 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2022 edition of ICD-10-CM D70. 1 became effective on October 1, 2021.
11.
Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter. T45. 1X5A is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
ICD-10 | Anemia, unspecified (D64. 9)
810 for Antineoplastic chemotherapy induced pancytopenia is a medical classification as listed by WHO under the range - Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism .
ICD-10 Code ICD-10 Description Assign when immunodeficiency is due to: D84. 821 Immunodeficiency due to drugs Medications that interfere with the immune system. These medications include immunosuppressants, corticosteroids, and chemotherapy.
G62. 0 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
During the hospitalization, she was restarted on chemotherapy, which caused profuse diarrhea, and the provider documented “diarrhea secondary to Cisplatin.” In ICD-10-CM, the Index to Diseases classifies drug-induced diarrhea to code K52. 1, Toxic gastroenteritis and colitis.
Anemia in neoplastic disease 1 D63.0 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. 2 The 2021 edition of ICD-10-CM D63.0 became effective on October 1, 2020. 3 This is the American ICD-10-CM version of D63.0 - other international versions of ICD-10 D63.0 may differ.
A type 1 excludes note is for used for when two conditions cannot occur together, such as a congenital form versus an acquired form of the same condition.
There are also codes Z85.6, Personal history of leukemia, and Z85.79, Personal history of other malignant neoplasms of lymphoid, hematopoietic and related tissues. If the documentation is unclear as to whether the leukemia has achieved remission, the provider should be queried.
When a primary malignancy has been previously excised or eradicated from its site and there is no further treatment directed to that site and there is no evidence of any existing primary malignancy at that site, a code from category Z85, Personal history of malignant neoplasm, should be used to indicate the former site of the malignancy. Any mention of extension, invasion, or metastasis to another site is coded as a secondary malignant neoplasm to that site. The secondary site may be the principal or first-listed with the Z85 code used as a secondary code.
These guidelines, developed by the Centers for Medicare and Medicaid Services ( CMS) and the National Center for Health Statistics ( NCHS) are a set of rules developed to assist medical coders in assigning the appropriate codes. The guidelines are based on the coding and sequencing instructions from the Tabular List and the Alphabetic Index in ICD-10-CM.
When a patient is admitted because of a primary neoplasm with metastasis and treatment is directed toward the secondary site only , the secondary neoplasm is designated as the principal diagnosis even though the primary malignancy is still present .
Chapter 2 of the ICD-10-CM contains the codes for most benign and all malignant neoplasms. Certain benign neoplasms , such as prostatic adenomas, may be found in the specific body system chapters. To properly code a neoplasm, it is necessary to determine from the record if the neoplasm is benign, in-situ, malignant, or of uncertain histologic behavior. If malignant, any secondary ( metastatic) sites should also be determined.
When a pregnant woman has a malignant neoplasm, a code from subcategory O9A.1 -, malignant neoplasm complicating pregnancy, childbirth, and the puerperium, should be sequenced first, followed by the appropriate code from Chapter 2 to indicate the type of neoplasm. Encounter for complication associated with a neoplasm.
These tumors may represent different primaries or metastatic disease, depending on the site. Should the documentation be unclear, the provider should be queried as to the status of each tumor so that the correct codes can be assigned.